• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy.

作者信息

Westin Jason, McLaughlin Peter

出版信息

Leuk Lymphoma. 2010 Jan;51(1):161-3. doi: 10.3109/10428190903324244.

DOI:10.3109/10428190903324244
PMID:19863175
Abstract
摘要

相似文献

1
De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy.原发性CD5+弥漫性大B细胞淋巴瘤：具有不良特征、无病生存率低且传统治疗效果不佳的独特亚组。
Leuk Lymphoma. 2010 Jan;51(1):161-3. doi: 10.3109/10428190903324244.
2
De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.原发性CD5+弥漫性大B细胞淋巴瘤：在接受利妥昔单抗治疗的大型多中心队列中，有无干细胞移植的不良结局
Am J Hematol. 2016 Jun;91(4):395-9. doi: 10.1002/ajh.24299.
3
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.免疫组化双打击评分是利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗弥漫性大 B 细胞淋巴瘤患者预后的强有力预测指标。
J Clin Oncol. 2012 Oct 1;30(28):3460-7. doi: 10.1200/JCO.2011.41.4342. Epub 2012 Jun 4.
4
[Rituximab plus Autologous Hemotopoietic Stem Cell Transplantation for The Treatment of CD5 Positive Diffuse Large B Cell Lymphoma with Autoimmune Hemolytic Anemia].利妥昔单抗联合自体造血干细胞移植治疗伴自身免疫性溶血性贫血的CD5阳性弥漫性大B细胞淋巴瘤
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Jun;24(3):722-6. doi: 10.7534/j.issn.1009-2137.2016.03.016.
5
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.年轻的非生发中心 B 细胞样弥漫性大 B 细胞淋巴瘤患者从 ACVBP 联合利妥昔单抗强化化疗中获益优于 CHOP 联合利妥昔单抗：来自 Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma 研究协会 III 期试验 LNH 03-2B 的数据分析。
J Clin Oncol. 2014 Dec 10;32(35):3996-4003. doi: 10.1200/JCO.2013.54.9493. Epub 2014 Nov 10.
6
A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.nm23-H1 表达在接受环磷酰胺+表柔比星+长春新碱+泼尼松+利妥昔单抗方案治疗的弥漫大 B 细胞淋巴瘤中的研究。
Ann Hematol. 2011 Feb;90(2):185-92. doi: 10.1007/s00277-010-1060-8. Epub 2010 Sep 1.
7
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗新诊断弥漫性大 B 细胞非霍奇金淋巴瘤患者：14 天与 21 天周期强化剂量的 3 期比较。
Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22.
8
CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.CHOP-R疗法克服了弥漫性大B细胞淋巴瘤中BCL-2表达的不良预后影响。
Leuk Lymphoma. 2007 Jun;48(6):1102-9. doi: 10.1080/10428190701344881.
9
Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab.蛋白激酶 C-β II 在弥漫性大 B 细胞淋巴瘤中的表达预示着蒽环类药物为基础的化疗联合或不联合利妥昔单抗的预后不良。
Leuk Lymphoma. 2009 Oct;50(10):1666-75. doi: 10.1080/10428190903165233.
10
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.短疗程R-CHOP方案序贯（90）钇-伊布替尼单抗治疗既往未治疗的高危老年弥漫性大B细胞淋巴瘤患者：7年长期结果
Blood Cancer J. 2016 May 13;6(5):e425. doi: 10.1038/bcj.2016.29.

引用本文的文献

1
Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens.双打击弥漫性大B细胞淋巴瘤中CD5表达的预后分析及剂量调整EPOCH联合利妥昔单抗/R-CHOP方案治疗患者的疗效比较
Blood Lymphat Cancer. 2019 Aug 19;9:33-43. doi: 10.2147/BLCTT.S216292. eCollection 2019.
2
Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.韩国人 CD5 阳性弥漫性大 B 细胞淋巴瘤的特征：BCL2 和 MYC 双表达者的高发生率。
PLoS One. 2019 Oct 23;14(10):e0224247. doi: 10.1371/journal.pone.0224247. eCollection 2019.
3
Fever of Unknown Origin due to Primary Hepatic Diffuse Large B-cell Lymphoma: A Case Report.
原发性肝脏弥漫性大B细胞淋巴瘤所致不明原因发热：一例报告
Cureus. 2019 Mar 11;11(3):e4220. doi: 10.7759/cureus.4220.
4
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.西方国家原发性CD5+弥漫性大B细胞淋巴瘤的临床和生物学意义。
Oncotarget. 2015 Mar 20;6(8):5615-33. doi: 10.18632/oncotarget.3479.
5
Primary hepatosplenic CD5-positive diffuse large B-cell lymphoma: a case report with literature review.原发性肝脾CD5阳性弥漫性大B细胞淋巴瘤：一例报告并文献复习
Int J Clin Exp Pathol. 2013 Apr 15;6(5):985-9. Print 2013.